Johanna Magga

Johanna Magga

Auto-generated profile, based on publicly available information

Johanna Magga

Molecular Cardiology Group, Research Unit of Biomedicine and Internal Medicine University of Oulu Oulu Finland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RKRisto Kerkelä
Risto Kerkelä
JUJohanna Ulvila
Johanna Ulvila
JMJohanna Magga
Johanna Magga
Journal of the American Heart Association (JAHA) is an authoritative, peer-reviewed Open Access journal focusing on cardiovascular and cerebrovascular disease

7 February 2014 in Stem Cells
Verified
Journal Article
Open access
PDF file
VKVirve Kärkkäinen
Virve Kärkkäinen
YPYuriy Pomeshchik
Yuriy Pomeshchik
ESEkaterina Savchenko
Ekaterina Savchenko
HDHiramani Dhungana
Hiramani Dhungana
AKAntti Kurronen
Antti Kurronen
JKJari E. Koistinaho
Jari E. Koistinaho
Neural stem/progenitor cells (NPCs) proliferate and produce new neurons in neurogenic areas throughout the lifetime. While these cells represent potential therapeutic treatment of neurodegenerative diseases, regulation of neurogenesis is not completely understood. We show that deficiency of nuclear factor erythroid 2-related factor (Nrf2), a transcription factor induced in response to oxidative stress, prevents the ischemia-induced increase in newborn neurons in the subgranular zone of the dentate gyrus. Consistent with this finding, the growth of NPC neurospheres was increased by lentivirus-mediated overexpression of Nrf2 gene or by treatment with pyrrolidine dithiocarbamate (PDTC), an Nrf2 activating compound. Also, neuronal differentiation of NPCs was increased by Nrf2 overexpression or PDTC treatment but reduced by Nrf2 deficiency. To investigate the impact of Nrf2 on NPCs in Alzheimer's disease (AD), we treated NPCs with amyloid beta (Aβ), a toxic peptide associated with neurodegeneration and cognitive abnormalities in AD. We found that Aβ1–42-induced toxicity and reduction in neurosphere proliferation were prevented by Nrf2 overexpression, while Nrf2 deficiency enhanced the Aβ1–42-induced reduction of neuronal differentiation. On the other hand, Aβ1–40 had no effect on neurosphere proliferation in wt NPCs but increased the proliferation of Nrf2 overexpressing neurospheres and reduced it in Nrf2-deficient neurospheres. These results suggest that Nrf2 is essential for neuronal differentiation of NPCs, regulates injury-induced neurogenesis and provides protection against Aβ-induced NPC toxicity. Stem Cells 2014;32:1904–1916

1 March 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SJScott E. Jarvis
Scott E. Jarvis
JMJohanna M. Magga
Johanna M. Magga
ABAaron M. Beedle
Aaron M. Beedle
JBJanice E. A. Braun
Janice E. A. Braun
GZGerald Zamponi
Gerald Zamponi
The direct modulation of N-type calcium channels by G protein βγ subunits is considered a key factor in the regulation of neurotransmission. Some of the molecular determinants that govern the binding interaction of N-type channels and Gβγ have recently been identified (see, i.e., Zamponi, G. W., Bourinet, E., Nelson, D., Nargeot, J., and Snutch, T. P. (1997)Nature 385, 442–446); however, little is known about cellular mechanisms that modulate this interaction. Here we report that a protein of the presynaptic vesicle release complex, syntaxin 1A, mediates a crucial role in the tonic inhibition of N-type channels by Gβγ. When syntaxin 1A was coexpressed with (N-type) α1B + α2-δ + β1b channels in tsA-201 cells, the channels underwent a 18 mV negative shift in half-inactivation potential, as well as a pronounced tonic G protein inhibition as assessed by its reversal by strong membrane depolarizations. This tonic inhibition was dramatically attenuated following incubation with botulinum toxin C, indicating that syntaxin 1A expression was indeed responsible for the enhanced G protein modulation. However, when G protein βγ subunits were concomitantly coexpressed, the toxin became ineffective in removing G protein inhibition, suggesting that syntaxin 1A optimizes, rather than being required for G protein modulation of N-type channels. We also demonstrate that Gβγ physically binds to syntaxin 1A, and that syntaxin 1A can simultaneously interact with Gβγ and the synprint motif of the N-type channel II-III linker. Taken together, our experiments suggest a mechanism by which syntaxin 1A mediates a colocalization of G protein βγ subunits and N-type calcium channels, thus resulting in more effective G protein coupling to, and regulation of, the channel. Thus, the interactions between syntaxin, G proteins, and N-type calcium channels are part of the structural specialization of the presynaptic terminal.

26 November 2015 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
ÁPÁbel Perjés
Ábel Perjés
TKTeemu Kilpiö
Teemu Kilpiö
JUJohanna Ulvila
Johanna Ulvila
JMJohanna Magga
Johanna Magga
TATarja Alakoski
Tarja Alakoski
RKRisto Kerkelä
Risto Kerkelä

1 October 2000 in Neuron
Verified
Journal Article
Closed access
JMJohanna M. Magga
Johanna M. Magga
SJScott E. Jarvis
Scott E. Jarvis
MAMichelle I. Arnot
Michelle I. Arnot
GZGerald Zamponi
Gerald Zamponi
JBJanice E.A. Braun
Janice E.A. Braun

1 January 2010 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
JMJohanna Magga
Johanna Magga
LPLakshman Puli
Lakshman Puli
RPRea Pihlaja
Rea Pihlaja
KKKatja Marika Kanninen
Katja Marika Kanninen
SNSuvi Neulamaa
Suvi Neulamaa
MKMilla Koistinaho
Milla Koistinaho
Purified intravenous immunoglobulin (IVIG) obtained from the plasma of healthy humans is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. IVIG contains naturally occurring auto-antibodies, including antibodies (Abs) against β-amyloid (Aβ) peptides accumulating in the brains of Alzheimer's disease (AD) patients. IVIG has been shown to alleviate AD pathology when studied with mildly affected AD patients. Although its mechanisms-of-action have been broadly studied, it remains unresolved how IVIG affects the removal of natively formed brain Aβ deposits by primary astrocytes and microglia, two major cell types involved in the neuroinflammatory responses.